Adipocyte dysfunction is the driver of obesity and correlates with insulin resistance and the onset of type 2 diabetes. Protein kinase N1 (PKN1) is a serine/threonine kinase that has been shown to contribute to Glut4 translocation to the membrane and glucose transport. Here, we evaluated the role of PKN1 in glucose metabolism under insulin-resistant conditions in primary visceral adipose tissue (VAT) from 31 patients with obesity and in murine 3T3-L1 adipocytes. In addition, in vitro studies in human VAT samples and mouse adipocytes were conducted to investigate the role of PKN1 in the adipogenic maturation process and glucose homeostasis control. We show that insulin-resistant adipocytes present a decrease in PKN1 activation levels compared to nondiabetic control counterparts. We further show that PKN1 controls the adipogenesis process and glucose metabolism. PKN1-silenced adipocytes present a decrease in both differentiation process and glucose uptake, with a concomitant decrease in the expression levels of adipogenic markers, such as PPARγ, FABP4, adiponectin and CEBPα. Altogether, these results point to PKN1 as a regulator of key signaling pathways involved in adipocyte differentiation and as an emerging player of adipocyte insulin responsiveness. These findings may provide new therapeutic approaches for the management of insulin resistance in type 2 diabetes.
Weight-loss outcomes after bariatric surgery (BS) show interindividual variability that is not fully explained by clinical factors. In the OBEGEN study we previously developed a clinical-genetic score combining three clinical variables with nine single nucleotide polymorphisms to predict weight-loss success at 12-18 months after BS. In the present study we evaluated the usefulness of this clinical-genetic score to predict longitudinal weight-loss trajectories up to five years after BS. Multicenter retrospective cohort study including 342 adults who underwent Roux-en-Y gastric bypass or sleeve gastrectomy (2018-2020) with available genetic data. Patients were classified as into higher or lower predicted response groups using the OBEGEN cut-off (0.662). The primary outcome was percentage total weight loss (%TWL) assessed from 6 months to 5 years. Longitudinal trajectories were analyzed using linear mixed-effects models adjusted for baseline BMI, sex, type 2 diabetes, and center. Secondary outcomes included the proportion achieving >20% TWL and recurrent weight gain. Patients in the higher predicted response group achieved greater %TWL throughout follow-up than those in the lower predicted response group (adjusted β = 2.60%, p = 0.009). Differences emerged early after surgery and remained stable over time without progressive divergence. At 5 years, a higher proportion of patients in the higher predicted response group maintained >20% TWL (78.7% vs. 60.0%, p = 0.001). Discriminatory performance of response to BS was moderate but consistent (area under the receiver operating characteristic curve 0.674 at 1 year; 0.608 at 5 years). The OBEGEN clinical-genetic score stratifies patients into distinct medium-term weight-loss trajectories after bariatric surgery, supporting its utility as a preoperative tool for risk stratification and personalized management in obesity.